Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

NCT03616184 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT03616184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03616184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
Lead sponsor
University of Nebraska
Phase
Phase 2
Overall status
Completed
Start date
September 5, 2018
Completion date
June 12, 2023
Enrollment
49 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host-disease (gvhd)